<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Early and Prediagnostic Detection of Pancreatic Cancer from Computed Tomography - Health AI Hub</title>
    <meta name="description" content="This paper introduces ePAI, an artificial intelligence system designed for the early and prediagnostic detection of pancreatic ductal adenocarcinoma (PDAC) from">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Early and Prediagnostic Detection of Pancreatic Cancer from Computed Tomography</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2601.22134v1" target="_blank">2601.22134v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2026-01-29
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Wenxuan Li, Pedro R. A. S. Bassi, Lizhou Wu, Xinze Zhou, Yuxuan Zhao, Qi Chen, Szymon Plotka, Tianyu Lin, Zheren Zhu, Marisa Martin, Justin Caskey, Shanshan Jiang, Xiaoxi Chen, Jaroslaw B. ƒÜwikla, Artur Sankowski, Yaping Wu, Sergio Decherchi, Andrea Cavalli, Chandana Lall, Cristian Tomasetti, Yaxing Guo, Xuan Yu, Yuqing Cai, Hualin Qiao, Jie Bao, Chenhan Hu, Ximing Wang, Arkadiusz Sitek, Kai Ding, Heng Li, Meiyun Wang, Dexin Yu, Guang Zhang, Yang Yang, Kang Wang, Alan L. Yuille, Zongwei Zhou
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CV
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2601.22134v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2601.22134v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces ePAI, an artificial intelligence system designed for the early and prediagnostic detection of pancreatic ductal adenocarcinoma (PDAC) from computed tomography (CT) scans. ePAI demonstrated high accuracy and sensitivity in both internal and external validations, crucially detecting lesions up to 36 months before clinical diagnosis, often overlooked by radiologists. A multi-reader study confirmed ePAI's significant outperformance of board-certified radiologists in sensitivity for early PDAC detection.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Early detection is critical for improving the grim prognosis of PDAC, as timely diagnosis allows for potentially curative surgical resection. This AI system could transform PDAC management by identifying cancer at a stage when intervention is still possible, significantly impacting patient survival rates.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application, ePAI (early Pancreatic cancer detection with Artificial Intelligence), is designed as an assistive tool for radiologists to automatically and accurately detect pancreatic ductal adenocarcinoma (PDAC) from CT scans. It aims to identify small, previously overlooked lesions at a prediagnostic stage, potentially months before clinical diagnosis, thereby improving the chances for earlier intervention and better patient prognoses for one of the deadliest malignancies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Pancreatic ductal adenocarcinoma (PDAC) is frequently detected at late, inoperable stages, with lesions often overlooked on prediagnostic CT scans by human experts.</li>
                    
                    <li>The authors developed ePAI (early Pancreatic cancer detection with Artificial Intelligence), trained on 1,598 patient CT scans from a single medical center.</li>
                    
                    <li>In internal testing (1,009 patients), ePAI achieved an AUC of 0.939-0.999, 95.3% sensitivity, and 98.7% specificity for PDACs <2 cm, precisely localizing lesions as small as 2 mm.</li>
                    
                    <li>External validation across 6 centers (7,158 patients) showed robust performance with an AUC of 0.918-0.945, 91.5% sensitivity, and 88.0% specificity, localizing PDACs as small as 5 mm.</li>
                    
                    <li>ePAI successfully detected PDACs on prediagnostic CT scans 3 to 36 months before clinical diagnosis (median lead time of 347 days), identifying 75 out of 159 previously overlooked cases.</li>
                    
                    <li>A multi-reader study demonstrated ePAI significantly outperformed 30 board-certified radiologists with 50.3% higher sensitivity (P < 0.05), while maintaining a comparable specificity of 95.4% for early and prediagnostic detection.</li>
                    
                    <li>The findings suggest ePAI's strong potential as an assistive tool to significantly improve the early detection rate of pancreatic cancer.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved developing and training a deep learning-based artificial intelligence system, ePAI, using CT scan data. The system's performance was rigorously evaluated through an internal test set and an external validation cohort spanning multiple medical centers. Furthermore, a multi-reader study compared ePAI's diagnostic capabilities against those of 30 board-certified radiologists on prediagnostic CT scans.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>ePAI demonstrated superior performance in detecting small PDACs (<2cm) with internal test metrics of AUC 0.939-0.999, sensitivity 95.3%, and specificity 98.7%, localizing lesions down to 2 mm. External validation confirmed robustness with AUC 0.918-0.945, sensitivity 91.5%, and specificity 88.0%, localizing 5 mm lesions. Crucially, ePAI achieved prediagnostic detection in 75 of 159 patients with a median lead time of 347 days (3-36 months prior) and significantly outperformed radiologists by 50.3% in sensitivity (P < 0.05) at comparable specificity (95.4%).</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>ePAI has the potential to serve as a vital assistive tool for radiologists, significantly enhancing the early detection of pancreatic cancer. By identifying PDAC at an earlier, potentially resectable stage, it could substantially improve patient outcomes and survival rates, shifting the paradigm from late-stage palliative care to curative intervention.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state specific limitations of the study. However, implicit considerations might include the retrospective nature of identifying 'overlooked' lesions and the need for prospective validation in diverse clinical settings.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The findings suggest the potential for integrating ePAI into routine clinical workflows as an assistive diagnostic tool. Future research could focus on prospective clinical trials to further validate its utility in real-time screening scenarios and assess its impact on patient management and survival outcomes.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Radiology</span>
                    
                    <span class="tag">Gastroenterology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Pancreatic Cancer</span>
                    
                    <span class="tag tag-keyword">PDAC</span>
                    
                    <span class="tag tag-keyword">Artificial Intelligence</span>
                    
                    <span class="tag tag-keyword">Computed Tomography</span>
                    
                    <span class="tag tag-keyword">Early Detection</span>
                    
                    <span class="tag tag-keyword">Prediagnostic</span>
                    
                    <span class="tag tag-keyword">Machine Learning</span>
                    
                    <span class="tag tag-keyword">Radiology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest solid malignancies, is often detected at a late and inoperable stage. Retrospective reviews of prediagnostic CT scans, when conducted by expert radiologists aware that the patient later developed PDAC, frequently reveal lesions that were previously overlooked. To help detecting these lesions earlier, we developed an automated system named ePAI (early Pancreatic cancer detection with Artificial Intelligence). It was trained on data from 1,598 patients from a single medical center. In the internal test involving 1,009 patients, ePAI achieved an area under the receiver operating characteristic curve (AUC) of 0.939-0.999, a sensitivity of 95.3%, and a specificity of 98.7% for detecting small PDAC less than 2 cm in diameter, precisely localizing PDAC as small as 2 mm. In an external test involving 7,158 patients across 6 centers, ePAI achieved an AUC of 0.918-0.945, a sensitivity of 91.5%, and a specificity of 88.0%, precisely localizing PDAC as small as 5 mm. Importantly, ePAI detected PDACs on prediagnostic CT scans obtained 3 to 36 months before clinical diagnosis that had originally been overlooked by radiologists. It successfully detected and localized PDACs in 75 of 159 patients, with a median lead time of 347 days before clinical diagnosis. Our multi-reader study showed that ePAI significantly outperformed 30 board-certified radiologists by 50.3% (P < 0.05) in sensitivity while maintaining a comparable specificity of 95.4% in detecting PDACs early and prediagnostic. These findings suggest its potential of ePAI as an assistive tool to improve early detection of pancreatic cancer.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>